MARKET

ACOR

ACOR

Acorda Thrpeutcs
NASDAQ
13.21
+1.30
+10.92%
After Hours: 15.00 +1.79 +13.54% 16:19 03/28 EDT
OPEN
12.39
PREV CLOSE
11.91
HIGH
13.32
LOW
11.82
VOLUME
4.46K
TURNOVER
0
52 WEEK HIGH
24.20
52 WEEK LOW
8.98
MARKET CAP
16.41M
P/E (TTM)
-1.0294
1D
5D
1M
3M
1Y
5Y
Press Release: Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024. Acorda Therapeutics announces a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. A replay of the webcast will be available on the company's website.
Dow Jones · 3d ago
Weekly Report: what happened at ACOR last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at ACOR last week (0311-0315)?
Weekly Report · 03/18 09:24
Acorda Thrpeutcs: Current report
Press release · 03/13 22:17
Weekly Report: what happened at ACOR last week (0304-0308)?
Weekly Report · 03/11 09:24
Weekly Report: what happened at ACOR last week (0226-0301)?
Weekly Report · 03/04 09:25
Weekly Report: what happened at ACOR last week (0219-0223)?
Weekly Report · 02/26 09:26
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?
Acorda Therapeutics, Inc. (NASDAQ:ACOR) has US$181.0m in debt. The company produced negative earnings before interest and tax in the last 12 months. It has a negative revenue of US$111m, and a net debt of about US$148.6m. Debt is an important factor in assessing whether a company is risky. AcordaTherapeutics is a high risk stock and we think shareholders need to watch it closely. We've spotted 3 warning signs for Acord a Therapeutic.
Simply Wall St · 02/21 10:01
More
About ACOR
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The Company uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s commercial products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). Inbrija is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. Inbrija utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Webull offers Acorda Therapeutics Inc stock information, including NASDAQ: ACOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACOR stock methods without spending real money on the virtual paper trading platform.